Korean stocks with clinical trial filings
Filing on clinical trial plans or results (90 days). Add more filters below to narrow the list.
Add filters earnings · returns · ownership · events · caution · market · industry · sort
Shareholder returns
Ownership
News & events
Caution
Industry
AllElectronics & telecom equipmentMachinery & equipmentPublishing & softwarePharmaceuticalsChemicalsFinancial servicesWholesale tradeMedical, precision & optical instrumentsAutos & auto partsElectrical equipmentBasic metalsResearch & developmentFood productsRubber & plasticsFabricated metal productsFinancial & insurance support servicesRetailGeneral construction
33 Korean listed companies match this signal: filing on clinical trial plans or results (90 days). 9 are on KOSPI and 24 on KOSDAQ. Sorted by most news articles in the past 24 hours, the list starts with Hanmi Pharm, Celltrion and OliX Pharmaceuticals. 25 of them also carry a red flag such as losses or dilution; check the signals column.
Clinical trial filing 33
| Company | Articles 24h | Latest quarter op. profit | Dividend yield | Signals |
|---|---|---|---|---|
| Hanmi Pharm KOSPI · Pharmaceuticals | 44 | ₩131bn +117% | 0.8% | Profit +50% Revenue & profit growth Op. margin 20%+ Dividend grower Insider buying Clinical trial filing Share pledge |
| Celltrion KOSPI · Pharmaceutical ingredients | 41 | ₩452bn +86% | – | Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Buyback Insider buying Major holder adding Clinical trial filing Insider selling Share pledge |
| OliX Pharmaceuticals KOSDAQ · Medical & pharmaceutical R&D | 16 | −₩14.0bn | – | Clinical trial filing 4 quarters of losses |
| Inventage Lab KOSDAQ · Research & development | 14 | −₩10.3bn | – | Clinical trial filing 4 quarters of losses |
| Curocell KOSDAQ · Medical & pharmaceutical R&D | 13 | −₩9.7bn | – | Insider buying Clinical trial filing 4 quarters of losses |
| Dong-a ST KOSPI · Pharmaceuticals | 10 | ₩6.3bn | 1.4% | Turnaround Clinical trial filing |
| Daewon Pharmaceutical KOSPI · Pharmaceuticals | 10 | −₩9m | – | Clinical trial filing |
| EuBiologics KOSDAQ · Pharmaceuticals | 7 | ₩8.6bn -24% | – | Op. margin 20%+ Supply contract Clinical trial filing |
| AbClon KOSDAQ · Medical supplies | 5 | −₩6.3bn | – | Supply contract Clinical trial filing 4 quarters of losses |
| Samsung Epis Holdings KOSPI · Other financial services | 4 | ₩58.7bn | – | Clinical trial filing |
| Hanmi Science KOSPI · Other financial services | 2 | ₩59.1bn +71% | 0.8% | Profit +50% Major holder adding Clinical trial filing Insider selling Share pledge |
| ST Pharm KOSDAQ · Pharmaceuticals | 1 | ₩18.3bn +42% | 0.3% | Revenue +30% Revenue & profit growth Clinical trial filing Share pledge |
| Inventera KOSDAQ · Medical & pharmaceutical R&D | 1 | −₩2.5bn | – | Clinical trial filing |
| Dong-A Socio Holdings KOSPI · Other financial services | 0 | ₩39.0bn +38% | 1.6% | Revenue & profit growth Insider buying Supply contract Clinical trial filing Share pledge |
| Abion KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩4.3bn | – | Supply contract Clinical trial filing 4 quarters of losses Insider selling |
| Keeps Biopharma KOSDAQ · Pharmaceuticals | 0 | −₩2.4bn | – | Revenue +30% Insider buying Clinical trial filing Share pledge |
| Shaperon KOSDAQ · Pharmaceutical ingredients | 0 | −₩3.1bn | – | Clinical trial filing 4 quarters of losses Insider selling Delisting / halt risk |
| Aimed Bio KOSDAQ · Medical & pharmaceutical R&D | 0 | ₩8.5bn +280% | – | Profit +50% Op. margin 20%+ Clinical trial filing |
| GI Innovation KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩14.4bn | – | Clinical trial filing 4 quarters of losses Share pledge |
| QuadMedicine KOSDAQ · Pharmaceutical ingredients | 0 | −₩2.4bn | – | Insider buying Clinical trial filing Swung to loss |
| Samsung Pharmaceutical KOSPI · Pharmaceuticals | 0 | −₩5.0bn | – | Clinical trial filing 4 quarters of losses |
| Shinpoong Pharmaceutical KOSPI · Pharmaceuticals | 0 | −₩8.0bn -263% | – | Clinical trial filing Swung to loss |
| Anterogen KOSDAQ · Wholesale trade | 0 | −₩478m | – | Clinical trial filing 4 quarters of losses |
| Genematrix KOSDAQ · Medical & pharmaceutical R&D | 0 | ₩393m | – | Turnaround Clinical trial filing |
| SillaJen KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩6.2bn | – | Clinical trial filing 4 quarters of losses |
| Kangstem Biotech KOSDAQ · Pharmaceutical ingredients | 0 | −₩6.1bn | – | Clinical trial filing 4 quarters of losses |
| FutureChem KOSDAQ · Pharmaceuticals | 0 | −₩3.2bn | – | Clinical trial filing 4 quarters of losses |
| MedPacto KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩3.6bn | – | Clinical trial filing 4 quarters of losses |
| Aptabio Therapeutics KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩3.6bn | – | Clinical trial filing 4 quarters of losses |
| Cellbion KOSDAQ · Pharmaceuticals | 0 | −₩2.6bn | – | Clinical trial filing 4 quarters of losses |
| Voronoi KOSDAQ · Research & development | 0 | −₩29.3bn | – | Clinical trial filing 4 quarters of losses |
| ImmuneOncia Therapeutics KOSDAQ · Medical & pharmaceutical R&D | 0 | −₩4.3bn | – | Clinical trial filing 4 quarters of losses |
| INGENIA Therapeutics KOSDAQ · Medical & pharmaceutical R&D | 0 | ₩0m | – | Turnaround Clinical trial filing |
Signals are generated automatically from DART filings (quarterly results, ownership reports, major-event reports and filing titles) and news counts. Prices and trading flows are not included. Not investment advice.
What this list means
Filings on clinical trial approvals or results. The trial phase and whether primary endpoints were met are key, and company statements can differ from regulators' conclusions.
Lists are generated automatically from filings and are not investment advice.